Society of Interventional Radiology Position Statement on Percutaneous Radiofrequency Ablation for the Treatment of Liver Tumors
Received 30 May 2008; received in revised form 5 September 2008; accepted 5 September 2008. published online 23 October 2008.
Focal tumor ablation—whether applied percutanously, laparoscopically, or by means of open surgery—is an effective therapy for selected liver tumors. The choice of liver ablation as well as the choice between percutaneous and surgical approaches is dependent on tumor factors, patient factors, and other viable treatment options. Currently, the largest cumulative reported experience is with radiofrequency (RF) ablation of hepatocellular carcinoma and colorectal metastases. This document is a position statement of the Interventional Oncology Task Force and the Standards Division of the Society of Interventional Radiology regarding the use of percutaneous RF ablation for the treatment of liver tumors.
aDepartment of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, White 270, 55 Fruit St, Boston, MA 02114
bDepartment of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
cDepartment of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
dDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
eDepartment of Radiology, University of Western Ontario, London, Canada, and Peterborough Regional Health Center, Peterborough, Ontario, Canada
fDivision of Vascular & Interventional Radiology, Department of Medical Imaging, University of Toronto, University Health Network, Toronto, Ontario, Canada
Address correspondence to D.A.G.
D.A.G. is a paid consultant for Covidien. S.N.G. is a paid consultant for AngioDynamics.
ABSTRACT